Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Adenocarcinoma × Morphine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pain 17 Neoplasms 17 Cancer Pain 15 Pain, Postoperative 9 Chronic Pain 7 Agnosia 5 Colonic Neoplasms 4 Neoplasm Metastasis 3 Multiple Myeloma 3 Mucositis 3 Lymphoma, Follicular 3 Lymphoma 3 Leukemia, Myeloid, Acute 3 Leukemia, Biphenotypic, Acute 3 Leukemia 3 Colorectal Neoplasms 3 Breast Neoplasms 3 Wounds and Injuries 2 Waldenstrom Macroglobulinemia 2 Thrombocythemia, Essential 2 Supratentorial Neoplasms 2 Sezary Syndrome 2 Primary Myelofibrosis 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Precancerous Conditions 2 Polycythemia Vera 2 Pdgfra-Associated Chronic Eosinophilic Leukemia 2 Pancreatic Neoplasms 2 Pain, Intractable 2

Interventions

Oxaliplatin 42 Gemcitabine 41 Fluorouracil 37 Capecitabine 29 pembrolizumab 28 Leucovorin 26 Docetaxel 25 Cisplatin 24 Paclitaxel 21 Carboplatin 18 Bevacizumab 17 Irinotecan 16 130-nm albumin-bound paclitaxel 16 Pemetrexed 15 Radiotherapy 13 Albumin-Bound Paclitaxel 13 Nivolumab 12 Cyclophosphamide 10 Ramucirumab 9 Trastuzumab 7 Radiosurgery 7 cemiplimab 6 Taxes 6 Erlotinib Hydrochloride 6 Drug Therapy 6 zolbetuximab 5 trastuzumab deruxtecan 5 durvalumab 5 Sorafenib 5 S 1 (combination) 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05325164 2022-12-05

METHADOPT

Ottawa Hospital Research Institute

Phase 3 Withdrawn

Cancer Pain, Adenocarcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡